Squarepoint
KRYS icon

Squarepoint’s Krystal Biotech KRYS Stock Holding History

Squarepoint’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,500
Closed -$370K – 4642
2025
Q4 		$370K Buy
+1,500
New +$316K ﹤0.01% 3450
2024
Q4 		– Sell
-2,600
Closed -$473K – 5290
2024
Q3 		$473K Buy
+2,600
New +$501K ﹤0.01% 3134

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's KRYS Position: Q1 2026 in Review

Squarepoint opened a new position in Krystal Biotech (KRYS) in Q1 2026: 1,138 shares worth $294K. The stake represents ﹤0.01% of the portfolio and ranks #3731 among its holdings. This is a return to the name: Squarepoint previously reported a position in KRYS as recently as Q1 2025.

Squarepoint first reported a position in KRYS in Q4 2017 and has held it in 16 quarters since. The position peaked at $14.8M in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Squarepoint held 1,138 shares of Krystal Biotech worth $294K as of Q1 2026.
  • Krystal Biotech was a new Squarepoint position in Q1 2026.
  • Krystal Biotech made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3731 holding.
  • Squarepoint first reported a position in Krystal Biotech in Q4 2017 and has held it in 16 quarters since.
  • Squarepoint's Krystal Biotech position peaked at $14.8M in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.